Edwards Lifesciences Reports Strong Q1 Earnings and Raises 2026 Guidance
Edwards Lifesciences reported Q1 sales of $1.65 billion, up 12.7% YoY, exceeding expectations and raising 2026 revenue growth guidance to 9%–11%. The company's TAVR segment and TMTT therapies drove growth, with strong profitability metrics and margin expansion expected.
Topics: Earnings Guidance Update Healthcare Sector Revenue Growth TAVR Sales